Characteristics |
N (%) |
Median |
At Diagnosis |
|
|
Age, years |
256 (100%) |
56 (range 17-76) |
Gender |
|
|
Male |
158 (62%) |
|
Female |
98 (38%) |
|
Extra-nodal sites |
|
|
0 |
171 (66.7%) |
|
1 |
64 (25%) |
|
2 |
17 (7%) |
|
3 |
3 (1%) |
|
4 |
1 (0.3%) |
|
LDH (U/L) |
256 (100%) |
234.5 (range 110-2400) |
PS |
|
|
0 |
56 (22%) |
|
1 |
192 (75%) |
|
2 |
8 (3%) |
|
Stage |
|
|
I |
32 (13%) |
|
II |
43 (17%) |
|
III |
57 (22%) |
|
IV |
124 (48%) |
|
IPI risk factors |
|
|
Age, years |
|
|
> 60 |
94 (37%) |
|
≤ 60 |
162 (63%) |
|
Extra-nodal sites |
|
|
> 1 |
21 (8%) |
|
≤ 1 |
235 (92%) |
|
LDH (U/L) |
|
|
abnormal |
126 (49%) |
|
normal |
130 (51%) |
|
PS |
|
|
> 1 |
8 (3%) |
|
≤ 1 |
248 (97%) |
|
Stage |
|
|
I/II |
75 (29%) |
|
III/IV |
181 (71%) |
|
IPI score |
|
|
0 |
32 (13%) |
|
1 |
79 (31%) |
|
2 |
101 (39%) |
|
3 |
38 (15%) |
|
4 |
6 (2%) |
|
IPI |
|
|
≥ 2 |
145 (57%) |
|
< 2 |
111 (43%) |
|
At relapse |
|
|
Age-R |
|
|
> 60 |
98 (38%) |
|
≤ 60 |
158 (62%) |
|
Extra nodal sites-R |
|
|
> 1 |
29 (11%) |
|
≤ 1 |
227 (89%) |
|
LDH-R |
|
|
abnormal |
120 (47%) |
|
normal |
136 (53%) |
|
PS-R |
|
|
> 1 |
30 (12%) |
|
≤ 1 |
226 (88%) |
|
Stage-R |
|
|
I/II |
109 (43%) |
|
III/IV |
147 (57%) |
|
IPI-R |
|
|
> 2 |
60 (23%) |
|
≤ 2 |
196 (77%) |
|
Pre-transplant Rituximab |
|
|
No |
137 (54%) |
|
Yes |
119 (46%) |
|
Number of prior treatments before transplant |
|
|
2 |
220 (86%) |
|
3 |
33 (135) |
|
4 |
3 (1%) |
|
At Transplant |
|
|
Age, years |
256 (100%) |
57 (range 17-77) |
Outcome prior to transplant |
|
|
CR |
66 (26%) |
|
PR |
190 (74%) |
|
Conditioning regimens |
|
|
CTX/TBI |
6 (2%) |
|
BEAC |
47 (19%) |
|
BEAM |
203 (79%) |
|
Infused CD34 |
256 (100%) |
3.4 (range 2.0-14.9) |
Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites at
relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse;
PS = performance status; PS-R; performance status at relapse; Stage-R = stage
at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic
Index at relapse; CTX= cyclophosphamide; TBI = Total body irradiation: BEAC
= BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM = BCNU, etoposide,
Ara-C, and melphalan; CR = complete remission; PR = partial response. |